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Summary: High-dimensional biomarkers such as genomics are increasingly being measured in randomized clinical
trials. Consequently, there is a growing interest in developing methods that improve the power to detect biomarker-
treatment interactions. We adapt recently proposed two-stage interaction detecting procedures in the setting of
randomized clinical trials. We also propose a new stage 1 multivariate screening strategy using ridge regression to
account for correlations among biomarkers. For this multivariate screening, we prove the asymptotic between-stage
independence, required for family-wise error rate control, under biomarker-treatment independence. Simulation results
show that in various scenarios, the ridge regression screening procedure can provide substantially greater power than
the traditional one-biomarker-at-a-time screening procedure in highly correlated data. We also exemplify our approach
in two real clinical trial data applications.
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1. Introduction
Recent developments in medicine have seen a shift toward targeted therapeutics. It has been
shown that individual variability can often contribute to differences in response to the same
treatment. For example, patients with leukemia respond to the treatment with all-trans
retinoic acid if they have the PML-RARA translocation (Sawyers, 2008). Conversely, use of
some drugs can lead to increased risk to patients with specific genetic variants, e.g. the Class
II allele HLA-DRB1*07:01 has been associated with lapatinib-induced liver injury (Parham
et al., 2016). Detecting such interactions between biomarkers and treatments in randomized
clinical trials is of growing interest.
Discovering biomarker-treatment interactions helps identify predictive biomarkers: biomark-
ers which influence treatment efficacy can be used to find the subgroup of patients who are
most likely to benefit from the new treatment, as well as to predict subgroup treatment
effects. Consequently, new adaptive design approaches can be used in settings where there
are genetically-driven subgroups to improve efficiency (Wason et al., 2015). Furthermore, the
discovery of novel biomarker-treatment interactions may result in the identification of new
disease susceptibility loci, providing insights into the biology of diseases. Such outcomes are
very much aligned with the goals of precision medicine: to enable the provision of “the right
drug at the right dose to the right patient” (Collins and Varmus, 2015).
Detecting biomarker-treatment interactions in large-scale studies of human populations
is a non-trivial task, which faces several challenging problems (McAllister et al., 2017).
Traditional interaction analysis, using regression models to test biomarker-treatment in-
teractions one biomarker at a time, may suffer from poor power when there is a large
multiple testing burden, for example when performing such analysis on a genome-wide
scale for genetic biomarkers. Standard genotyping microarrays measure half a million or
more variants and, when combined with whole genome imputation, can lead to millions
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of biomarkers to consider. Another type of omics, metabolomics - the measurement of
metabolite concentrations in the body - may have a more direct effect on drug efficacy
and is also becoming increasingly widely assayed (Beckonert et al., 2007).
In the context of gene-environment interaction studies, there is now a significant literature
of statistical methods, which exploit aspects of the study design to improve power thus
mitigating the multiple testing burden. These include case-only tests (Piegorsch et al., 1994),
empirical Bayes (Mukherjee and Chatterjee, 2008), Bayesian model averaging (Li and Conti,
2008), and two-stage tests with different screening procedures (Kooperberg and LeBlanc,
2008; Murcray et al., 2008; Gauderman et al., 2013; Wason and Dudbridge, 2012). To alleviate
the multiple testing burden, two-stage methods use independent information from the data
to perform a screening test to select a subset of genetic biomarkers, and then only test inter-
actions within this reduced set. Since there is a clear analogy to gene-environment interaction
problems, in this paper, we will examine how existing gene-environment interaction testing
methods may be modified so that they are transferable to the biomarker-treatment setting
(Dai et al., 2009, 2016; Wang and Dai, 2016). One significant drawback of the traditional
two-stage approach testing each biomarker one at a time is that the univariate screening tests
will harm power of the overall two-stage procedure when there exist substantial correlations
between biomarkers. We also propose a novel screening test in this two-stage framework,
which utilizes ridge regression to model correlated high-dimensional data at stage 1. We
prove that this new two-stage method is able to preserve the overall family-wise error rate
given independence between the treatment and biomarkers. Furthermore, it is shown by
simulations and real data applications that the new method can provide better performance
than traditional one-biomarker-at-a-time approaches for correlated biomarkers. In the con-
text of more general variable selection settings, screening strategies have been explored to
focus algorithms on a reduced search space (Fan and Lv, 2008; Wang and Leng, 2016). In this
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work, we explore the use of variable pre-screening specifically to help identify interactions
and the condition required for controlling the family-wise error rate.
2. Methods
2.1 Standard Single-Step One-Biomarker-at-a-Time Interaction Tests
In the context of randomized clinical trials, one can test each biomarker in turn for a
biomarker-treatment interaction using the following linear model
E(Yi | Xij, Ti) = β0j + βXjXij + βTTi + βXj×TXij × Ti (1)
with Yi denoting the response outcome, Ti the binary treatment-control indicator, and
Xi1, . . . , Xim representing the values of m biomarkers, for the ith patient. The null hypothesis
βXj×T = 0 could be tested for each j = 1, . . . ,m, e.g. using a Wald test with the Bonferroni
correction applied to preserve the family-wise error rate.
The number of biomarkers m to be considered is potentially large. Given the desired
overall family-wise error rate α, a Bonferroni correction (Dunn, 1961) requires an adjusted
significance level for each individual test to be α/m. Although the Bonferroni correction is
typically used for its simplicity and flexibility, with regard to our interest in high-dimensional
interaction testing it is worth exploring whether other procedures are able to provide im-
proved efficiency. In Web Appendix A, we demonstrate theoretically some alternative family-
wise error rate controlling methods (Šidák, 1967; Holm, 1979) can only provide a small
improvement across the settings we consider in this paper: when m is large and only a small
subset of biomarkers have true interactions with treatment.
2.2 Two-Stage Interaction Tests with Some Existing Screening Methods
Two-stage approaches use a screening test as a filtering stage (stage 1) to select a subset of
biomarkers, and then in stage 2, only test interactions within the reduced set of biomarkers,
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thus increasing power. To preserve the overall family-wise error rate, two-stage approaches
rely on the stage 1 screening tests being independent of the final stage 2 tests.
A common stage 1 screening test used in two-stage interaction testing is a marginal
association test (Kooperberg and LeBlanc, 2008). Considering this type of screening test in
the clinical trial setting, the marginal effect of a biomarker on the outcome can be measured
in a regression model of the form
E(Yi | Xij) = δ0j + δXjXij (2)
The screening procedure is conducted by testing the null hypothesis δXj = 0 for j = 1, . . . ,m,
with a pre-specified significance level α1 ∈ (0, 1). In stage 2, one then tests interactions using
the one-biomarker-at-a-time model (1) within the set of biomarkers selected at stage 1.
Another way to utilize stage 1 information is to test all m biomarkers in stage 2 using
weighted significance levels, that add up to the targeted error rate α, based on ordered
biomarkers from stage 1. One possible weighting scheme (Ionita-Laza et al., 2007) is: the
B most significant biomarkers, i.e. with lowest p-values in stage 1, are compared with an
adjusted significance level (α/2)/B, the next 2B biomarkers are compared with (α/4)/(2B),
..., the next 2kB biomarkers are compared with (α/2k+1)/(2kB), and so on.
The motivation of conducting marginal association tests to screen for candidate interaction
tests is that we expect a biomarker that has an interaction with the treatment for the
disease will also show some level of marginal association with the response. However, it is
also possible that the biomarker’s main association with response and the interaction effect
may be in opposite directions. When this is the case, a marginal screening strategy would
downgrade due to the first stage test statistic having low power.
To preserve the overall family-wise error rate, a key requirement to apply the two-stage
approach is the independence between stage 1 and 2 tests. Both Murcray et al. (2008) and Dai
et al. (2012) proved that: with stage 1 and 2 test statistics being asymptotically independent
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and m∗ defined as the number of stage 1 selected biomarkers, using a Bonferroni adjusted
significance level α = α/m∗ at stage 2 to test interactions within the reduced set is sufficient
to preserve the overall family-wise error rate of the two-stage procedure under α.
In the context of gene-environment interaction studies, an alternative type of screening is
testing the correlation between a gene and the environmental factor (Murcray et al., 2008).
This type of screening requires case-control sampling for a rare response endpoint, thus it can
be useful for detecting biomarker-treatment interactions in large prevention trials. However,
such a screening procedure is not generally applicable in randomized clinical trials, where
the rare response condition does not hold. In this case, the trial population represents the
entire dataset and cases (responders) are not “oversampled”. We make this argument and
also discuss the applicability of other related proposals more formally in Web Appendix B.
2.3 New Stage 1 Penalized Regression Screening Procedure Accounting for
Biomarker-Biomarker Correlations
One drawback of existing two-stage interaction testing procedures is that biomarkers are
only screened one at a time in stage 1. This ignores correlations between the biomarkers.
In a high-dimensional, low-sample-size data set, an ordinary multivariate regression analysis
testing each predictor, while accounting for correlations with the other predictors, is not
feasible. Therefore we considered penalized regression methods to model correlated high-
dimensional data. These techniques have improved the development of risk predictors from
high-dimensional genomic information (Wu et al., 2009; Newcombe et al., 2017).
We propose a new stage 1 multivariate screening test of the following form to account for
biomarker-biomarker correlations




This multivariate version of the marginal association screening test also includes the treat-
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ment main effect term. This is necessary to preserve the independence between stage 1
screening and stage 2 interaction tests as described later.
To fit this multivariate model, we use ridge regression, which applies regularization to avoid
overfitting in high-dimensional low-sample-size problems. Typically, the objective of ridge
regression is to minimize a loss function Ln along with an L2 regularization term: Ln(δ) +





and λn is the regularization parameter. Ridge shrinks
all the estimated coefficients towards zero, but will not set them exactly to zero. For use in a
two-stage interaction testing strategy, we propose ordering the biomarkers based on the ridge
coefficients obtained from stage 1, and then use the resulting ranking to determine varying
significance thresholds across buckets of markers during stage 2 one-at-a-time interaction
tests according to the weighting scheme described in Section 2.2.
2.4 Proof of Independence between Stage 1 Penalized Regression Screening and Stage 2
Standard Interaction Tests
In this section, we show that independence between stage 1 and stage 2 test statistics holds
for stage 1 ridge regression screening tests.
For the ith subject, let Yi denote the outcome variable, X i = (Ti, Xi1, . . . , Xim)
T be a
vector of the binary treatment-control indicator and m biomarkers. Consider the proposed
stage 1 marginal association screening test based on the multivariate model of the form
E(Yi |X i) = XTi δ
where δ = (δT , δX1 , . . . , δXm)
T . The model underlying the stage 2 standard one-biomarker-
at-a-time interaction test is of the form
E(Yi | V ij) = V Tijβj (j = 1, . . . ,m)
where V ij = (Xij, Ti, XijTi)
T and βj = (βXj , βTj , βXj×T )
T . The above forms ignore intercepts
without loss of generality. Homogeneity of variance is assumed, i.e. var(Yi |X i) and var(Yi |
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V ij) are assumed to be constants. We first show the between-stage asymptotic independence
for the stage 1 multivariate regression marginal association estimator without regularization.
Theorem 1: For any j = 1, . . . ,m, if Xij is independent of Ti, and, E(Ti) = 0 or
E(Xij) = 0 (i.e. Ti or Xij is centered around 0), then under the null hypothesis βXj×T = 0,
cov{n1/2(δ̂0Xj − δXj), n
1/2(β̂Xj×T − βXj×T )} → 0
in probability, where δ̂0Xj and β̂Xj×T are the maximum likelihood estimators for unknown
parameters δXj and βXj×T respectively without regularization (i.e. λn = 0).
The proof is provided in the appendix. Previous works (Dai et al., 2012) have demon-
strated that the stage 1 univariate marginal association screening tests are independent
with the stage 2 one-biomarker-at-a-time interaction tests. Theorem 1 extends this to show
independence still holds when stage 1 tests are extended to a multivariate regression. Our
proof relies on: 1) the inclusion of the treatment main effect in the multivariate regression
of the form (3); 2) an assumption of independence between the treatment assignment and
biomarker values, which is valid in randomized clinical trials. The proof in Dai et al. (2012)
for the univariate marginal association screening tests is more general; it does not depend
on biomarker-environment independence and it also holds for generalized linear models.
Next we establish the asymptotic distribution of the ridge estimator.
Lemma 1: Under standard regularity conditions (Van der Vaart, 2000, p. 51-52) and if
λn = O(n
1/2), i.e. limn→∞ λn/n
1/2 = λ0 > 0, then
n1/2(δ̂
λ
− δ)→ N (−2λ0Σ−1δ, σ2Σ−1)
in distribution, where δ̂
λ
is the ridge estimator, N is a normal distribution, σ and Σ are a
constant and an invertible constant matrix.
Based on the asymptotic results derived in Lemma 1 and Theorem 1, we are able to
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prove the asymptotic independence between the stage 1 ridge marginal association screening
estimator and the stage 2 one-at-a-time interaction estimator in the following corollary.
Corollary 1: For any j = 1, . . . ,m, if Xij is independent of Ti, and, E(Ti) = 0 or
E(Xij) = 0 (i.e. Ti or Xij is centered around 0), then under the null hypothesis βXj×T = 0,
cov{n1/2(δ̂λXj − δXj), n
1/2(β̂Xj×T − βXj×T )} → 0
in probability, where δ̂λXj is the maximum likelihood estimator with the ridge penalty.
Proofs of Lemma 1 and Corollary 1 are given in Web Appendices C and D.
3. Results
3.1 Simulation Study
To evaluate performance of our proposed biomarker-treatment interaction testing procedure
described above, we generated simulated data sets, each having m = 1, 000 biomarkers. Data
were simulated under the model Yi = β0 +βTTi +
∑m
j=1(βXjXij +βXj×TXij ×Ti) + εi, where
the treatment main effect was set to βT = 0.5 and the intercept β0 = 0. We partitioned
the 1, 000 biomarkers into 50 clusters of correlated biomarkers, containing 20 biomarkers
each. We denote the clusters C1 = {X1, . . . , X20}, C2 = {X21, . . . , X40}, and so on. One
biomarker in the first cluster was ascribed a main effect and an interaction effect, i.e. βX1 =
0.5 and βX1×T = 1. Four other biomarkers in four other different clusters were ascribed main
effects on the trait without interactions, i.e. βX21 = βX41 = βX61 = βX81 = 1.5. All other
biomarkers do not have direct effects on the outcome. Each biomarker Xj was generated
from a standard normal distributionN (0, 1) and the binary treatment assignment was drawn
from a Bernoulli(0.5) distribution, while εi was generated from a normal distribution with
standard deviation 5. In this case, the proportion of variance explained by the true model is
0.292. We consider two types of correlation patterns among biomarkers: 1) The 20 biomarkers
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within each cluster are correlated with each other (ρ = 0.6), but there are no correlations
between biomarkers in different clusters; 2) All biomarkers are independent of one another
(ρ = 0). For each scenario, 1, 000 replicate data sets were generated to estimate power and
family-wise error rates. Power for all the approaches is defined according to the idea of
“cluster discoveries” in Brzyski et al. (2017) as pr(reject at least one Hj0 for any Xj ∈ Ci |
at least one Hk1 is true for any Xk ∈ Ci), where H
j
0 is the null hypothesis for Xj and H
k
1 is
the alternative hypothesis for Xk.
Four different screening procedures are compared: 1) “Univariate screening (threshold)”:
A selection of biomarkers to take forward to stage 2 is based on significance in a regression
of response on the biomarkers one at a time, of the form (2). A significance level α1 = 0.05 is
used without adjustment for each stage 1 biomarker test. 2) “Univariate screening (rank)”:
All biomarkers are taken forward to stage 2, and the stage 1 p-value ranking is used to
conduct a stage 2 weighted hypothesis test described in Section 2.2 with B = 5 {a number
recommended by Gauderman et al. (2013)}. 3) “Ridge screening (rank)”: Ridge regression
is used to estimate marginal effects at stage 1. Then all biomarkers are ordered based on
these stage 1 coefficients and the rank will be used by the stage 2 weighted hypothesis
test with B = 5. The optimal λn is chosen based on 5-fold cross-validation errors. The R
package glmnet (Friedman et al., 2010) was used. 4) “No screening”: A standard single-
step interaction test of the form (1), targeting an overall family-wise error rate α = 0.05, is
performed as a baseline comparator (with a Bonferroni correction applied with m = 1, 000)
and also as the stage 2 test for all three two-stage approaches described above.
[Figure 1 about here.]
In Fig. 1(a), with highly correlated biomarkers, the proposed ridge regression screening
procedure demonstrated substantially higher power than the univariate screening procedures,
showing a clear benefit of accounting for correlations between the biomarkers at stage
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1. For the univariate screening procedures, all the biomarkers with univariate marginal
signals, including X1, . . . , X100, were likely to be retained after screening in the “threshold”
approach or land into the top buckets at stage 2 in the “rank” approach. In contrast, the
ridge screening procedure considered the effect of each biomarker, adjusted for all other
biomarkers, and therefore tended to ascribe less evidence to biomarkers whose marginal
associations were exaggerated by correlation with the true signal(s). Thus, biomarkers with
true marginal associations, which are more likely to have interactions, tended to be ranked in
the top buckets because of accounting for biomarker-biomarker correlations at stage 1. This
enhanced the power of the overall two-stage approach compared with using the univariate
screening procedures. In Fig. 1(b), with independent biomarkers, where the multivariate
regression is not required for unbiased effect estimation, the univariate screening and the
ridge screening procedures using weighted hypothesis tests perform similarly. All three two-
stage tests outperformed the single-step interaction test by providing better power at the
same family-wise error rate level whether biomarkers are correlated or independent.
In Fig. 1(c), we simulated scenarios with one biomarker having an interaction, no correla-
tions among the biomarkers, and changed only the main effect of the interacting biomarker
βX1 , i.e. main effects of the other four biomarkers were the same as the previous scenario.
The sample size was fixed at 1, 500. Fig. 1(c) reveals that there are some special cases, in
which the main and interaction effect parameters are in opposite directions such that they
cancel out, where all two-stage approaches give lower power than a single-step test.
In Fig. 1(d), we used the previous scenario with one biomarker having an interaction
(biomarker correlation ρ = 0.6, sample size of 1, 500) as the base, and changed only the
main effects of the four biomarkers with main effects alone βX21 , βX41 , βX61 , βX81 . Fig. 1(d)
shows that power of all four tests decreases with increasing effect sizes of main-effect only
biomarkers, because the proportion of variation explained by the interaction-effect biomarker
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decreases. The univariate screening using weighted hypothesis testing performs worse than
the single-step test when effect sizes of four main-effect biomarkers become too large. This
is because a large number of biomarkers that only have marginal associations, and no
interaction, tend to fall into the top buckets, thus the bucket size allocated to the true
interaction signal can lead to a more stringent significance threshold than that allocated
by the single-step test through the Bonferroni adjustment accounting for all m biomarkers.
The ridge screening strategy still outperforms the single-step test, despite the biomarkers
with marginal effects only exhibiting very strong stage 1 associations; their many correlated
proxies are still screened out through multivariate modelling.
In Web Appendix E, we summarize family-wise error rates in different scenarios, which
shows no inflation for all the screening procedures. We also provide additional simulation
results. Relative patterns of performance among the screening strategies were consistent with
the results described above, demonstrating the robustness of our method and findings.
3.2 Data Applications
In addition to validating our methods through simulations, we exemplified our approaches
in two real data applications.
We first applied our approaches to data from the randomized controlled trial START
(Fonagy et al., 2020), which is composed of 684 participants aged from 11 to 17 with antisocial
behavior, half of whom were treated with management as usual (the control arm) and the rest
were treated with multisystemic therapy followed by management as usual (the treatment
arm). We used a secondary outcome of this trial, the 18 months’ follow-up outcome from
Inventory of Callous and Unemotional Traits, as the continuous outcome and applied our
interaction testing procedures to detect covariates having interactions with the treatment. We
excluded covariates with more than 10% missing data and used mean imputation to replace
missing values for covariates with less than 10% missing data. As a result, 75 covariates were
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included in the analysis. Correlation among these covariates is generally low (a correlation
plot is provided in Web Appendix F).
We performed all four screening procedures described in the previous section with a
significance level of α = 0.05 and did not find any significant interactions. The top covariates
from each of the univariate screening and ridge screening procedures are presented in Table 1,
which shows that the selected covariates from these two procedures are similar in this data
set where covariates have low correlation.
In the second application, we applied our approaches retrospectively to a publicly available
dataset with high-dimensional gene expression biomarkers (the PREVAIL trial) (Muscedere
et al., 2018). The dataset is a phase II randomized trial which aimed to evaluate the efficacy
of lactoferrin as a preventative measure for hospital-acquired infections. Gene expression
data are available for 61 patients from the National Center for Biotechnology Information
(NCBI) website (GSE118657). Of the 61 patients, 32 patients were in the lactoferrin group,
and the remaining patients were in the placebo group. We used the Sequential Organ Failure
Assessment (SOFA) score measuring change in organ function post-randomization as the
continuous response endpoint. From a total of 49, 495 genes, we restricted our analysis to
the 10, 000 probes with the highest variability.
All four methods described in the previous section with a significance level of α = 0.05 did
not find any significant biomarker-treatment interactions. A list of the top biomarkers from
different marginal screening procedures is presented in Table 1. The rankings of selected
covariates are notably different between the ridge regression screening and the univariate
screening procedures, likely owing to the high correlation among the biomarkers.
In addition, we examined the empirical correlation between stage 1 ridge screening and
stage 2 interaction test statistics applied in the above two real data sets. Table 2 summarizes
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results from Pearson correlation tests, which shows that the empirical correlation between
stages is close to zero and in all cases the 95% confidence interval contains zero as expected.
[Table 1 about here.]
[Table 2 about here.]
4. Discussion
We propose, for the first time with formal justification, the use of ridge regression in a
two-stage interaction testing framework for identifying biomarker signatures of treatment
efficacy in randomized clinical trials. Interaction testing frameworks which are designed to
scale to large numbers of covariates will become ever more important as -omics technologies
continue to drop in price and become routinely measured in clinical trials. Naturally, there
will be variation in the level of correlation among different sets of -omics biomarkers from
one setting to the next. For instance, when there is a strong apriori hypothesis of which genes
influence treatment efficacy, such that a panel of genetic markers are all taken from the same
region, pairwise correlations will be stronger on average compared to a genome-wide panel
of variants, because local genetic correlations tend to be much stronger than long-range
correlations (known as linkage disequilibrium decay). Similarly, considering transcriptomics,
correlations will be stronger when focusing on a subset of genes that correspond to the same
pathway. Therefore the ridge screening approach will be particularly well motivated when
related biomarkers of apriori interest have been pre-selected, for instance from a gene region
or pathway. These biomarker sets will tend to exhibit the strongest correlation structures,
and so will benefit the most from multivariate modeling during stage 1 screening.
It is known that ridge regression has a tendency to average effects across strongly corre-
lated covariates. This phenomenon is not desirable for a screening strategy since it could
inflate the number of non-interacting biomarkers being put forward to stage 2. Thus, lasso
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(Tibshirani, 1996), as an alternative penalized regression model which does not exhibit this
effect-averaging behavior, may be expected to perform better. However, as lasso uses a L1
penalty which is not a smooth function, it is challenging to prove it meets the between-
stage independence requirement to preserve the overall family-wise error rate in two-stage
approaches. Since the main goal of employing the penalized regression screening procedures
in stage 1 is to account for biomarker-biomarker correlations, some less computationally
intensive multiple testing correction methods for correlated tests might be beneficial (Nyholt,
2004; Gao et al., 2008). However, applying such methods which calculate an “effective”
number of independent tests to the single-step interaction test in a limited set of simulations
did not offer any power improvement when controlling for the same family-wise error rate
(results not shown). We suggest further investigation in how to incorporate these methods
into the two-stage interaction framework including a formal justification of the family-wise
error rate control as a topic of future work.
We also showed that there exist special cases where our proposed two-stage screening
strategy offers no benefit, e.g. the case when the main effect of a biomarker and its interaction
effect with the treatment to the response are in opposite directions, which reduces the
strength of the marginal association (sometimes leaving no detectable marginal effect) for
true interactions. We suggest exploring the weighting scheme thus changing how much stage
1 information to be used in the following stage 2 tests as a future topic for investigation.
Another technical caveat was shown by Sun et al. (2018) that, for logistic regression, the
interaction estimator under treatment misspecification can be biased when the biomarker is
associated either indirectly or directly with the outcome. This is a generic issue to interaction
modeling using logistic regression, but could manifest in our framework as an elevated
family-wise error rate at stage 2 one-biomarker-a-time tests. Therefore, we highlight that,
currently, our theoretical work only guarantees family-wise error rate control when using
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linear regression. The extent to which this bias might inflate family-wise error rates when
applying our framework using logistic regression, and potential corrections, will be the topic
of future work.
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Appendix
Proof of Theorem 1
Based on the unified approach to proving between-stage asymptotic independence by Dai
et al. (2012), we need to evaluate the covariance matrix A−11 BA
−1
2 , where
A1 = E[(X iX
T
i ){Yi − E(Yi |X i)}2]
B = E[(X iV
T
ij){Yi − E(Yi |X i)}{Yi − E(Yi | V ij)}]
A2 = E[(V ijV
T
ij){Yi − E(Yi | V ij)}2]
We simplify the expression of B as
B = E[(X iV
T
ij){Y 2i − YiE(Yi |X i)− YiE(Yi | V ij) + E(Yi |X i)E(Yi | V ij)}]
= E[(X iV
T
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which uses the law of iterated expectations, the fact that X i includes V ij under the null
hypothesis βXj×T = 0, and assumes homogeneity of variance, i.e. var(Yi |X i) is a constant.
Similarly, we have A1 = E(X iX
T
i )var(Yi |X i) and A2 = E(V ijV Tij)var(Yi | V ij). Thus,
A−11 BA
−1
2 ∝ E(X iXTi )−1E(X iV Tij)E(V ijV Tij)−1



























· · E(TiXij)E(T 2i Xij)− E(T 2i )E(TiX2ij)
· · E(TiXij)E(TiX2ij)− E(X2ij)E(T 2i Xij)
· · E(X2ij)E(T 2i )− E(TiXij)2

Thus, for the (m + 1) × 3 matrix E(X iV Tij)E(V ijV Tij)−1, the (k + 1)th element (k =








i Xij)− E(T 2i )E(TiX2ij)
E(TiXij)E(TiX
2





= E(Ti)var(Ti)E(Xij){E(XikXij)E(Xij)− E(Xik)E(X2ij)} = 0
which uses the independence between Ti and Xij, and the assumption E(Ti) = 0 or E(Xij) =






−1 by E(X iX
T
i )
−1 completes the covariance matrix,
the last column of which are all zeros. Thus, for any j = 1, . . . ,m, we have cov{n1/2(δ̂0Xj −
δXj), n
1/2(β̂Xj×T − βXj×T )} → 0 in probability.
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Figure 1. Comparison of two-stage interaction tests with different screening testing
procedures. Four were compared: univariate screening (threshold) (long dashes), univariate
screening (rank) (short dashes), ridge screening (rank) (dot-dash), and no screening (solid).
The four panels represent: (a) highly correlated biomarkers (ρ = 0.6), (b) independent
biomarkers (ρ = 0), (c) independent biomarkers (ρ = 0, sample size of 1, 500), changing
the main effect of the interacting biomarker βX1 , (d) highly correlated biomarkers (ρ = 0.6,
sample size of 1, 500), changing the main effects of the four biomarkers βX21 , βX41 , βX61 , βX81 .
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Table 1
Top covariates from different stage 1 marginal screening procedures
START trial
Univariate screening Ridge screening
1 Total Inventory of Callous and Unemo-
tional Traits
Total Inventory of Callous and Unemo-
tional Traits
2 Total Antisocial Beliefs and Attitudes
Scale
Total Antisocial Beliefs and Attitudes
Scale
3 Strengths & Difficulties Conduct Prob-
lems Score
Strengths & Difficulties Conduct Prob-
lems Score
4 Strengths & Difficulties ProSocial Be-
haviour Score
Strengths & Difficulties ProSocial Be-
haviour Score
5 Strengths & Difficulties Hyperactivity
Score
Strengths & Difficulties Hyperactivity
Score
6 Volume of self reported delinquency ex-
cluding violence towards siblings
Volume of self reported delinquency ex-
cluding violence towards siblings
7 Strengths & Difficulties Total Difficulties
Score
Strengths & Difficulties Total Difficulties
Score
8 IQ IQ
9 Variety of self reported delinquency ex-
cluding violence towards siblings
Parental reported total Inventory of Cal-
lous and Unemotional Traits
10 Parent reported Strengths & Difficulties
Conduct Problems Score
Alabama Positive Parental Involvement
Score
PREVAIL trial
Univariate screening Ridge screening
1 11715617 a at 11715488 s at
2 11749774 x at 11715489 a at
3 11725694 at 11739745 a at
4 11746124 x at 11749774 x at
5 11739745 a at 11746124 x at
6 11747047 a at 11747047 a at
7 11715488 s at 11728717 at
8 11720970 at 11725694 at
9 11751473 a at 11716479 s at
10 11756156 s at 11752423 a at
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Table 2




95% confidence interval (-0.188, 0.271) (-0.019, 0.020)
